AMC REPRESENTATIVE PUBLICATIONS

2005 Publications

Kaplan LD, Lee JY, Ambinder RJ, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT: Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin’s lymphoma: AMC 010. Blood, May 24 2005 [Epub ahead of print]

Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Tooney NK, Cabral L, Whitby D, Barger GN, Dittmer DP, Harrington WJ Jr. Azidothymidine inhibits NF-kappa B and induces EB virus gene expression in Burkitt’s lymphoma. Blood 106:235-240, 2005.

2004 Publications

Chan ATC, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, Kwan WH, Leung TW-T, Johnson PJ, Ambinder RF. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors in patients. JCO 22(8):1373-1381, 2004. (LAB based).

Bundow D, Aboulafia DM. Potential drug interaction with paclitaxel in highly active antiretroviral therapy in two patients with AIDS-associated Kaposi’s sarcoma. Am J Clin Oncol 2004:1:81-84

Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi Sarcoma: Advances in Target Discovery and Treatment. AIDS Reader 14: 1-8, 2004.

2003 Publications

Dittmer D, Transcription Profile of Kaposi’s Sarcoma-associated Herpesvirus in Primary Kaposi’s Sarcoma Lesions as Determined by Real-time PCR Arrays, Cancer Research 63(9):2010-2015, 2003. (LAB based).

Ghosh SK, Wood C, Boise LH, Mian AM, Deyev V, Feuer G, Toomey NL, Shank NC, Cabral L, Barber GN, Harrington W, Jr, Potentiation of TRAIL-Induced Apoptosis in Primary Effusion Lymphoma through Azidothymidine-mediated Inhibition of NF-kappaB, Blood 101(6):2321-2327, 2003. (LAB based)

Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF and Caligiuri MA, Experimental Treatment of Epstein-Barr Virus-associated Primary System Lymphoma, Cancer Research 63:965-971, 2003.

2002 Publications

Aboulafia DM Interluekin-2,ganciclovir and high-dose zidovudine for the treatment of AIDS-associated primary central nervous lymphoma. Clin Infect DIS. 2002:34;1660-1662

Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Ratner L, Pluda JM, Figg WD, Krown SE and Dezube BJ. Matrix Metalloproetinease inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: a phase I AIDS Malignancy Consortium Study. JCO 20:153-159, 2002. (AMC011)

Miles SA, Dezube BJ, Lee JY, Fletcher MA, Saville MW, Kaplan LD, Groopman J, Scadden DT, Cooley T, Krown SE, Von Roenn J, Friedman-Kien A for the AIDS Malignancy Consortium. Anti-tumor activity of oral 9-cis retinoic acid in HIV infected patients with Kaposi’s sarcoma: a multicenter trial of the AIDS Malignancy Consortium. AIDS 16:421-429, 2002. (AMC002)

Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ghannoum M, Dowlati A, Renne R, Arts E, Whalen C, Lederman MM, Remick SC, Therapeutic Challenges of AIDS-related Non-Hodgkin’s Lymphoma in the United States and East Africa, J Natl Cancer Inst 94(10):718-732, May 2002.

2001 Publications

Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B and Straus D for the AIDS Malignancy Consortium. Chemotherapy for HIV-associated non-Hodgkin’s Lymphoma in Combination with Highly Active Antiretroviral Therapy. JCO 19(8):2165-2170, 2001. (AMC005)

Toomey NL, Deyev V, Wood C, Boise LH, Scott D, Liu LH, Cabral L, Podack ER, Barber GN, Harrington W, Jr, Induction of TRAIL Mediated Suicide Program by Interferon Alpha in Primary Effusion Lymphoma, Oncogene 20:7029-7040, 2001.

2000 Publications

Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS, Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-related Kaposi’s Sarcoma, JCO 18(4):716-723, Feb 2000.

Submitted Publications

Aboulafia DM, Ratner L, Miles SA, Lee JY, Harrington WS Jr for the AMC. Antiviral and immunomodulatory treatment for HIV-associated primary CNS lymphoma: AMC pilot study 019. (submitted)

Krown SE, Lee JY, Lin L, Fischl MA, Ambinder RA, Von Roenn JH: A phase I trial of protease inhibitor-based antiretroviral therapy with recombinant interferon Alfa-2b in patients with HIV-related Kaposi’s sarcoma.. (submitted).

Lin L, Lee J, Kaplan L, Dezube B, Noy A, Krown S, Yu Y, Hayward GS, Ambinder RF: Chemotherapy in AIDS-associated lymphoma leads to the disappearance of KSHV viremia. (Submitted).

Noy A, Scadden D, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S and Gill P for the AIDS Malignancy Consortium and IM862 Study Team. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s Sarcoma in a phase III trial, but highlights sustained, potent effect of HAART. Submitted for publication. (AMC013)

In Press Publications

Woodberry T. Henry LM, O’Connor PG, David JK, Suscovich TJ, Martin JN, Osmond D, Kedes DH, Lee J, Walker BD, Scadden DT, Brander C. Impact of HIV co-infection and viral loads on the detection ofcytotoxic T-lymphocyte responses to Kaposi’s Sarcoma associated herpesvirus (KSHV/HHV8_ LANA (ORF-73) and ORF-65 proteins. Journal of Infectious Diseases, in press.

2005 Abstracts

Aboulafia DM, Ratner L, Miles SA, Lee JY and Harrington WJ: AMC 019: A Pilot Study of Antiviral and Immunomodular Treatment for HIV-associated Primary CNS Lymphoma (PCNSL). Submitted for presentation at the International AIDS Malignancy Conference, September 2005.

Palefsky J, Berry M, Jay N, Krogstad M, Darragh T, Lee J. AMC 035: A phase I/II trial of SGN-00101 in the treatment of high-grade anal intraepithelial neoplasia (AIN) in HIV-positive individuals. Submitted for presentation at the International AIDS Malignancy Conference, September 2005.

2004 Abstracts

Dezube BJ for the AIDS Malignancy Consortium. Angiogenesis inhibitor COL-3 in the treatment of HIV-related Kaposi’s Sarcoma (KS): a phase II AIDS Malignancy Consortium Study. 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2004. (AMC027)

Lee J for the AIDS Malignancy Consortium. Pain and appearance are related to response to treatment in AIDS-related Kaposi’s Sarcoma. 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2004. (AMC002 and AMC013)

Lin L for the AIDS Malignancy Consortium. KSHV (HHV8) DNA in Peripheral Blood of Patients with AIDS-NHL and the Impact of Chemotherapy. 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2004. (LAB based)

2003 Abstracts

Dezube BJ, Tseng G, Fugelso D, Greenberg H, Nasser I, Wei LJ, Chatis PA, Microarray Expression Profile in High-Grade and Low-Grade Squamous Intraepithelial Lesions, 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003.

Kaplan LD, and Scadden DT for the AIDS Malignancies Consortium, No Benefit from Rituximab in a Randomized Ph III Trial of CHOP with or without Rituximab for Patients with HIV-Associated non-Hodgkin’s Lymphoma: AIDS Malignancies Consortium Study 010, 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, Maryland, April 2003.

Koon H, Bubley G, Pantanowitz L, Masiello D, Proper J, Weeden W, Smith B, Crosby K, Tahan SR, Dezube BJ, AIDS-related Kaposi’s Sarcoma: Imatinab Mesylate-Induced Regression in c-KIT Positive Disease, 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003.

Orem J, Otieno MW, Banura C, Katongole-Mbidde E, Fu P, Johnson J, Ness A, Reynolds S, Black J, Feigal E, Whalen C, Remick SC, Prospective Screening for AIDS-Related Non-Hodgkin’s Lymphoma (AR-NHL) Patients (PTS) in East Africa as Part of a Clinical Trial, 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003.

Otieno MW, Orem J, Banura C, Katongole-Mbidde E, Johnson J, Ness A, Reynolds S, Black J, Feigal E, Fu P, Whalen C, Remick SC, Preliminary Observations Using Dose-Modified Oral Combination Chemotherapy (DMOCC) For AIDS-Related Non-Hodgkin’s Lymphoma (AR-NHL) in East Africa: Toxicity & Vital Status, 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003.

Pantanowitz L, Tahan SR, Pinkus GS, Dezube BJ, Morphology and Mechanisms of Regression in AIDS-Related Kaposi’s Sarcoma (KS), 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003.

Von Roenn JH for the AIDS Malignancy Consortium. Phase I-II trial of BMS-275291 in patients with HIV-related Kaposi’s Sarcoma: a multicenter trial of the AIDS Malignancy Consortium. 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2003. (AMC024)

Woodberry T, Henry L, O’Connor P, Davis J, Lee J, Kaplan L, Khayrallah M, Osmond D, Martin J, Scadden D, Brander C and the AIDS Malignancy Consortium. Mediated immune response to KSHV ORF65 and ORF73 in individuals with and without KS. 7th International AIDS Malignancy Conference, Bethesda, Maryland, April 2003. (LAB based)

Kaplan LD, Lee J, Caligiuri M, Von Roenn J, Levine A, Harrington W and Scadden D for the AIDS Associated Malignancies Consortium. A randomized phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with or without Rituximab for patients with HIV-associated non-Hodgkin’s lymphoma: AIDS Malignancies Consortium Study 010. American Society of Clinical Oncology Meeting, Chicago, IL, June 2003. (AMC010)

Lin L, Ambinder RF, Fisher DC, Mauch P for the AIDS Malignancy Consortium. Epstein-Barr Virus Load in Plasma of Patients with AIDS Malignancy Reflects EB Viremia and Free EB Viral DNA (DNA-emia) Whereas in EBV(+)Hodgkins Lymphoma It Reflects Only DNA-emia. Blood 102 (11), Abstract #4850, November 16, 2003. (LAB based)

Kaplan LD, Lee J, Scadden DT. No benefit from Rituximab in a randomized phase III trial of CHOP with or without Rituximab for patients with HIV-associated non-Hodgkin’s lymphoma: Updated data from the AIDS Malignancies Consortium Study 010. American Society of Hematology Meeting, San Diego, CA, December 2003. (AMC010)

2002 Abstracts

Lin L, Kaplan L, Lee J, Chadburn A, Cesarman E, Herman JG, Ambinder RF and the AIDS Malignancy Consortium. Monitoring Epstein-Barr Virus Load in Peripheral Blood in AIDS-Related Lymphoma Patients: An AIDS Malignancy Consortium Laboratory Study. American Society of Hematology Meeting, Philadelphia, PA, December 2002. (LAB based)

Noy A, Gill P, Scadden D, Lee J, Dezube B, Aboulafia D, Tulpule A, Walmsley S for the AIDS Malignancy Consortium and IM862 Team. Angiogenesis Inhibitor IM862 Is Ineffective against AIDS-KS in a Randomized, Placebo Controlled Trial. 6th International AIDS Malignancy Conference, Bethesda, MD April 2002. (AMC013)

2001 Abstracts

Krown SE. Developmental therapy for Kaposi’s sarcoma: Major issues, Fifth International Conference on Maliganancies in AIDS and Other Immunodeficiencies, Bethesda, MD, April 2001. (Abstract 535)

Cianfrocca M, Cooley TP, Tan S, et al, Angiogenesis inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma (KS): final clinical analysis and report of effects on matrix metalloproteinase (MMP) and growth factor levels. 5th International AIDS Malignancy Conference. Bethesda, MD, May 2001.

2000 Abstracts

Cianfrocca M, Cooley TP, Lee J, Scadden DT, Ratner L, Dezube BJ: Angiogenesis inhibitor Col-3 in the treatment of HIV-related Kaposi’s Sarcoma: a phase I AIDS Malignancy Consortium Study. 4th International AIDS Malignancy Conference, Bethesda, MD, May 2000. (AMC011)

1999 Abstracts

Ratner L, Redden D, Hamzeh F, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B and Straus D, for the AIDS Malignancy Consortium (AMC), Chemotherapy for HIV-associated Non-Hodgkin’s Lymphoma (HIV-NHL) in Combination with Highly Active Antiretroviral Therapy (HAART) is not Associated with excessive Toxicity, 3rd International AIDS Malignancy Conference, Bethesda, MD, May 1999.

1998 Abstracts

Friedman-Kien A, Dezube B, Lee J, Groopman J, Saville W, Scadden DT, Debruge J, Miles S and the AMC 002 Team, Oral 9-cis Retinoic Acid is active in AIDS-Related Kaposi’s Sarcoma: AIDS-Associated Malignancy Consortium Study 002, 2nd International AIDS Malignancy Conference, Bethesda, Maryland, April 1998.

Lee J, Miles SA, Dezube B, Kaplan L, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien A and the AMC 002 Team. Recruitment in a Two-Stage Phase II Trial of AIDS Kaposi’s Sarcoma. 2nd International AIDS Malignancy Conference, Bethesda, MD, April 1998. (AMC002)

Lee J, Miles S, and Friedman-Kien A for the NCI AIDS Malignancies Consortium. Suspending Enrollment in a Two-Stage Phase II AIDS Malignancies Consortium Trial of AIDS Kaposi’s Sarcoma Patients. Society for Clinical Trials, Atlanta, Georgia, May 1998. (AMC002)

Miles SA, Dezube B, Lee J, Groopman J, Saville W, Scadden D, Debruge J, Friedman-Kien and the AMC 002 Team. Oral LGD1057 is Active in AIDS Related Kaposi’s Sarcoma: An AIDS Malignancies Consortium Trial (AMC-002). American Society of Clinical Oncology, Los Angeles, CA, May 1998. (AMC002)

Straus D, Redden D, Hamzeh F, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B and Ratner L for the AIDS Malignancy Consortium (AMC), Excessive Toxicity is not Seen with Low-Dose Chemotherapy for HIV-associated Non-Hodgkin’s Lymphoma (HIV-NHL) in Combination with Highly Active Antiretroviral Therapy (HAART), American Society of Hematology Meeting, Miami, Florida, December 1998.

1997 Abstracts

Feigal EG, Von Roenn J, Justice R, Yarchoan R, Krown S, Pluda J, Arbuck S, Murgo A, McCabe M, Ungerleider R, Wittes R. Kaposi’s sarcoma response criteria: Issues identified by NCI, FDA, and AMC. J Acq Immune Defic Syndr Hum Retroviral 14: A22, 1997 (Abstract 24).